EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.4 | pefabloc | - |
Sus scrofa | |
3.4.21.4 | ulinastatin | - |
Sus scrofa |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.4 | Sus scrofa | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.21.4 | pancreas | - |
Sus scrofa | - |
3.4.21.4 | pancreatic acinar cell | - |
Sus scrofa | - |
3.4.21.4 | pancreatic islet | - |
Sus scrofa | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.4 | N-benzoyl-L-arginine ethyl ester + H2O | - |
Sus scrofa | N-benzoyl-L-arginine + ethanol | - |
? |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.21.4 | 25 | - |
assay at | Sus scrofa |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.4.21.4 | malfunction | trypsin from pancreatic acinar cells destroys islets. Thus pancreatic slet transplantation which has emerged as an effective therapy and potential cure for type 1 diabetes mellitus, requires inhibition of trypsin activity by ulinastatin or pefabloc, optimization of islet preservation using the two-layer method, TLM, overview | Sus scrofa |